NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Eisai officials said the new study recruited 1,795 people with earlier Alzheimer's disease and amyloid beta in the brain. Participants received either a 10 mg per kilogram dose every two weeks ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get worse after they stop treatment. CNBC.

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of adverse reactions that may have held back its uptake in the ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...